Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABLTS:0R44 82 Return-on-Tangible-Asset is 21.04% as of Jun. 2026, which is 330% above its 10-year median of 4.89. GuruFocus rates LTS:0R44 with a GF Score™ of 82/100 and a GF Value™ of kr33.40 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, C-Rad AB ranks better than 85.48% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. C-Rad AB's annualizedNet Income for the quarter that ended in Jun. 2026 was kr96.8 Mil. C-Rad AB's average total tangible assets for the quarter that ended in Jun. 2026 was kr460.0 Mil. Therefore, C-Rad AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 21.04%.
The historical rank and industry rank for C-Rad AB's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0R44'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -51.63 Med: 4.89 Max: 20.23
Current: 10.89
During the past 13 years, C-Rad AB's highest Return-on-Tangible-Asset was 20.23%. The lowest was -51.63%. And the median was 4.89%.
LTS:0R44's Return-on-Tangible-Asset is ranked better than 85.48% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs LTS:0R44: 10.89
C-Rad AB (LTS:0R44) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
C-Rad AB Return-on-Tangible-Asset Related Terms
C-Rad AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, C-Rad AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 21.04% mean?
C-Rad AB (LTS:0R44) has a Return-on-Tangible-Asset of 21.04% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on C-Rad AB and its competitors. This is 330% above median its historical median of 4.89. According to the industry distribution chart, C-Rad AB ranks #124 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 14.5%.
Is C-Rad AB's Return-on-Tangible-Asset too high?
C-Rad AB's current Return-on-Tangible-Asset of 21.04% is 330% above median its 10-year median of 4.89. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. C-Rad AB's value of 21.04% is 3063.9% above this industry median. Based on the distribution chart, C-Rad AB ranks #124 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, C-Rad AB has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #124 out of 854 companies for Return-on-Tangible-Asset. This places C-Rad AB in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.67. C-Rad AB's value of 21.04% is 3063.9% above this benchmark. While the company's 10-year median is 4.89 vs. the industry median of 0.67, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Return-on-Tangible-Asset of 21.04% is 3063.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Return-on-Tangible-Asset is 21.04%, which is 330% above median its own 10-year median of 4.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Modestly Overvalued. The stock's GF Value™ is kr33.40, compared to a current price of kr37.90 — trading 13.5% above its estimated fair value. The current Return-on-Tangible-Asset is 21.04%, which is 330% above median its 10-year median of 4.89 and 3063.9% above the Medical Devices & Instruments industry median of 0.67. C-Rad AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Return-on-Tangible-Asset is 21.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr37.90 is trading 13.5% above its estimated GF Value™ of kr33.40.
GuruFocus considers C-Rad AB to be Modestly Overvalued.
Key valuation signals for LTS:0R44:
Return-on-Tangible-Asset: 21.04% (330% above median its 10-year median of 4.89)
GF Value™: kr33.40 vs. price of kr37.90 (13.5% above fair value)
Industry Position: 3063.9% above the Medical Devices & Instruments median (#124 of 854)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
82GF Score
Get the complete analysis for LTS:0R44
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
